^
    Back
    Association details:
    Biomarker:MAP1LC3B overexpression
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

    Published date:
    08/03/2020
    Excerpt:
    A higher expression of MAP1LC3B or LC3B protein was associated with longer survival and lower incidence of acquired resistance to checkpoint inhibitor blockade, suggesting LC3B as a potential predictive biomarker.
    DOI:
    10.1158/1078-0432.CCR-20-3463